[Bupivacaine 0.5% CO2 in spinal anesthesia].
The clinical usage of 0.5% bupivacaine-CO2 for spinal anaesthesia was tested in 45 patients. The use of bupivacaine CO2 is safe, segmental dificits were not observed. Compared to bupivacaine-HCl the latency period is shorter (7.7 min), whereas the duration of maximal analgesic spread (105 +/- 31 min) is identical. 93% of the patients had a complete motor blockade. The solubility of bupivacaine-CO2 in CSF (1.75 mg ml-1) is more than double the solubility of bupivacaine-HCl (0.8 mg ml-1), thus lowering the risk of precipitation.
D000775:Anesthesia, Spinal; D002045:Bupivacaine; D002245:Carbon Dioxide; D005260:Female; D005831:Genital Diseases, Female / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D009619:Nociceptors / Q000187:drug effects; D009435:Synaptic Transmission / Q000187:drug effects; D013697:Thermosensing / Q000187:drug effects; D014570:Urologic Diseases / Q000601:surgery
D002245:Carbon Dioxide; D002045:Bupivacaine
Bupivacain 0.5% CO2 in der Spinalanästhesie.